⏳ Fetching live dividend data...
Home › Calculator › RETA Dividend Calculator 2026
Reata Pharmaceuticals, Inc. · NASDAQ
Price: $172.36 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in RETA → $28.6K in 10 years · $2,195.74/month
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies for individuals afflicted with severe or life-threatening illnesses. A key focus is bardoxolone methyl (often referred to as bardoxolone), which is currently undergoing Phase 3 clinical trials for two distinct conditions: chronic kidney disease (CKD) associated with Alport syndrome, and a specific type of pulmonary arterial hypertension linked to connective tissue diseases. Bardoxolone also has an offering for autosomal dominant polycystic kidney disease (ADPKD). The pipeline further includes omaveloxolone, currently in Phase II development for Friedreich's ataxia. Reata is also advancing Phase 2 studies for various other chronic kidney diseases, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, and focal segmental glomerulosclerosis, among others. Beyond these, the company's earlier-stage development includes RTA 901, aimed at neurological disorders, and RTA 1701, which holds potential for treating a spectrum of autoimmune, inflammatory, and fibrotic conditions. The company has established strategic partnerships, including an agreement with Kyowa Kirin Co., Ltd. for the development and commercialization of bardoxolone across various renal, cardiovascular, diabetes, and metabolic indications within a broad territory spanning Japan, China, Hong Kong, Macao, South Korea, Taiwan, and several Southeast Asian nations (Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia). Additionally, Reata collaborates with AbbVie Inc. to jointly research, develop, and commercialize second- and later-generation Nrf2 activators for all indications excluding renal, cardiovascular, and metabolic applications. Originally incorporated in 2002 as Reata Discovery, Inc., the company officially became Reata Pharmaceuticals, Inc. in May 2005. It is headquartered in Plano, Texas.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open RETA position with:
Real after-tax yield depends on where you live and how you hold RETA.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 1.16% | -1.64% | $116 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 0.99% | -1.81% | $99 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 0.93% | -1.87% | $93 / yr |
| 🇬🇧 UK ISA | 0% | 1.16% | -1.64% | $116 / yr |
| 🇬🇧 UK Taxable | 8.75% | 1.06% | -1.74% | $106 / yr |
| 🇨🇦 TFSA | 0% | 1.16% | -1.64% | $116 / yr |
| 🇨🇦 CA Taxable | 25% | 0.87% | -1.93% | $87 / yr |
| 🇦🇺 Super (pension) | 15% | 0.99% | -1.81% | $99 / yr |
| 🇦🇺 AU Taxable | 30% | 0.81% | -1.99% | $81 / yr |
| 🇩🇪 DE Taxable | 26.375% | 0.85% | -1.95% | $85 / yr |
| 🇫🇷 FR Taxable | 30% | 0.81% | -1.99% | $81 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
RETA pays quarterly — 4 times per year. Next ex-div: TBD.
How RETA compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for RETA sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| D-Return | 2023-09-26 | 993,929 | — | — | ||
| D-Return | 2023-09-26 | 134 | $172.50 | $23.1K | ||
| D-Return | 2023-09-26 | 2,773 | $22.57 | $62.6K | ||
| D-Return | 2023-09-26 | 690 | $146.01 | $100.7K | ||
| D-Return | 2023-09-26 | 3,185 | $25.52 | $81.3K | ||
| D-Return | 2023-09-26 | 6,000 | $22.57 | $135.4K | ||
| D-Return | 2023-09-26 | 280 | $172.50 | $48.3K | ||
| D-Return | 2023-09-26 | 278,309 | — | — | ||
| D-Return | 2023-09-26 | 699 | $130.92 | $91.5K | ||
| D-Return | 2023-09-26 | 4,787 | $34.76 | $166.4K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the RETA dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Reata Pharmaceuticals, Inc. (RETA) is currently trading at $172.36, trading near its 52-week high. The current dividend yield is 1.16% based on an annual payout of $2.00 per share.
Reata Pharmaceuticals, Inc. (RETA) is a healthcare stock currently trading at $172.36 with a dividend yield of 1.16%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →